Monday’s market has seen swings in various stocks based on news and other factors. Today, stocks like Tesla (TSLA) are rallying, while stocks like Oracle (ORCL) are falling. Below are highlights of some of the biggest stock movers, from mega-caps to small caps.
Mega-Cap Movers ($200 billion+ market cap)
- Avago Technologies (AVGO) -4.31%
- Oracle Corp (ORCL) -4.26%
- Salesforce Com (CRM) -3.17%
- Alibaba-exch (BABA) -3.45%
- Tesla Motors (TSLA) +2.99%
- Philip Morris Intl (PM) +2.82%
- Eli Lilly And Co (LLY) +2.41%
- Lam Research Corp (LRCX) +2.12%
Large-Cap Stock Movers ($10-$200 billion market cap)
- Zillow Group Inc (ZG); Zillow (Z) Weakness Tied to Google Threat Chatter -12.14%
- Coherent (COHR) -10.16%
- Servicenow Inc (NOW); ServiceNow (NOW) said in talks to buy Armis for up to $7B -10.06%
- Iris Energy (IREN) -8.9%
- Circle Internet Group Inc (CRCL) -8.1%
- Yandex (NBIS) -6.96%
- Vector Acquisition (RKLB) -6.57%
- CoStar Group (CSGP) -7.33%
- CoreWeave (CRWV) -6.77%
- dMY Technology Group III (IONQ) -4.68%
Mid-Cap Stock Movers ($2-$10 billion market cap)
- Rmg Acquisition Corp II (RNW) -27.09%
- CleanSpark (CLSK) -15.47%
- Good Works Acquisition (CIFR) -12.38%
- Applied Blockchain (APLD) -12.36%
- Ikonics Corp (WULF) -10.22%
- Ondas (ONDS) -10.46%
- Hut 8 Mining PK (HUT) -13.73%
- B Riley Principal Merger Ii (EOSE) -7.38%
- NantKwest (IBRX) -7.35%
- Lyft ( -7.41%
Small-Cap Stock Movers ($300 million-$2 billion market cap)
- Kyverna Therapeutics (KYTX); Kyverna to present topline results from Phase 2 trial in stiff person syndrome +32.12%
- Immunome Inc (IMNM); Immunome to disclose Phase 3 RINGSIDE trial results for desmoid tumors +24.78%
- Fast Acquisition Corp II (FBYD) +9.69%
- TryHard Holdings (THH) -21.97%
- Centricus Acquisition (ARQQ) -10.56%
- Diginex Inc (DGNX) -11.36%
- WhiteFiber (WYFI) -11.54%
- CONL (CONL) -8.8%
- Khosla Ventures Acquisition Co II (NXDR) -9.7%
- MSTU (MSTU) -7.99%
For real-time, market-moving news, join Investing Pro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.








